A Growing Number of Biopharmas Leverage Veeva Compass Patient to Improve Commercialization
Get Alerts VEEV Hot Sheet
Join SI Premium – FREE
Modern commercial data helps organizations find new patients and HCPs
"We are using Veeva Compass Patient for many of our brands as it helps us find more HCPs and patients than traditional sources," said Sridutta Rao, executive director of commercial data and analytics solutions at Bayer. "Having unlimited access to a complete and modern dataset to generate insights for both retail prescriptions and in-office treatments gives us a better understanding of the entire patient journey."
Compass Patient is licensed for use at the brand level and includes unlimited data access to all patient data. The Compass data network includes more than 300 million patients in the
"Veeva Compass Patient is the next generation of patient data for life sciences," said
Veeva Compass Suite includes Veeva Compass Prescriber, projected prescriptions and procedures at the HCP, HCO, and ZIP level for retail and non-retail products, and Veeva Compass National, projected prescriptions and procedures at the state and national level for retail and non-retail products. Veeva Compass is part of Veeva Data Cloud, the modern, connected data platform for life sciences, which includes Veeva OpenData and Veeva Link.
Additional Information
For more on Veeva Compass, visit: veeva.com/Compass
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended
Contact:
Veeva Systems
925-226-8821
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/a-growing-number-of-biopharmas-leverage-veeva-compass-patient-to-improve-commercialization-302329758.html
SOURCE Veeva Systems
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX completes record $60 billion acquisition of AI coding platform Cursor
- Exzeo Group authorizes $25 million share repurchase program
- Optimum Communications gets NYSE non-compliance notice over stock price
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share